Last Updated: July 1, 2026

DEXTROAMP Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Dextroamp patents expire, and when can generic versions of Dextroamp launch?

Dextroamp is a drug marketed by Actavis Elizabeth, Ani Pharms, Ascent Pharms Inc, Aurolife Pharma Llc, Elite Labs Inc, Granules, Impax Labs, Lannett Co Inc, Lupin, Nesher Pharms, Ph Health, Rhodes Pharms, Specgx Llc, Sun Pharm Inds Inc, Sun Pharm Industries, Teva, Teva Pharms Usa, Accord Hlthcare, Alkem Labs Ltd, Alvogen, Barr, Cediprof Inc, Corepharma, Epic Pharma Llc, Nuvo Pharm, Oryza, Sandoz, Teva Pharms, Zydus Pharms, Barr Labs Inc, Able, Quagen, Senores Pharms, Strides Pharma, Strides Pharma Intl, Prasco, Tris Pharma Inc, Avanthi Inc, Azurity, Halsey, Lannett, Mast Mm, Novel Labs Inc, Purepac Pharm, Vitarine, and Winder Labs Llc. and is included in seventy-four NDAs.

The generic ingredient in DEXTROAMP is dextroamphetamine sulfate. There are eighteen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the dextroamphetamine sulfate profile page.

AI Deep Research
Ask!
Questions you can ask:
  • What is the 5 year forecast for DEXTROAMP?
  • What are the global sales for DEXTROAMP?
  • What is Average Wholesale Price for DEXTROAMP?
Summary for DEXTROAMP
US Patents:0
Applicants:46
NDAs:74
Drug Prices: Drug price information for DEXTROAMP
DailyMed Link:DEXTROAMP at DailyMed
Drug patent expirations by year for DEXTROAMP
Drug Prices for DEXTROAMP

See drug prices for DEXTROAMP

US Patents and Regulatory Information for DEXTROAMP

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Rhodes Pharms DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 210651-006 May 17, 2019 AB1 RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Lannett DEXTROAMPHETAMINE SULFATE dextroamphetamine sulfate TABLET;ORAL 083903-003 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Teva Pharms DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate TABLET;ORAL 040472-002 Sep 30, 2003 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Teva Pharms Usa DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 210876-003 Jan 31, 2022 AB2 RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Barr Labs Inc DEXTROAMP SACCHARATE,AMP ASPARTATE,DEXTROAMP SULFATE AND AMP SULFATE amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 076536-004 Feb 12, 2013 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Impax Labs DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 076852-005 Feb 16, 2016 AB1 RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Granules DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 217027-002 Jan 23, 2023 AB1 RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links